Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib versus physician's choice for germline BRCA-mutated advanced or metastatic breast cancer
2013-002716-28Phase 3Completed
- Sponsor
- Medivation
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of talazoparib in breast cancer (2 arms), sponsored by Medivation. Primary endpoint: Progression-Free Survival. Started Oct 2013; status: completed.
02
Drugs
talazoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-002716-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002716-28.